• م.م زهراء عبدالكريم ناشور
  • Zahraa abdulkareem
  • تدريسي : قسم تقنيات المختبرات الطبية
  • Teaching : Department of Medical lab technique
  • ماجستير علم الاحياء الجزيئي
  • Molecular Biology
  • zahraa.nashoor@esraa.edu.iq
  • zahraanashoor@gmail.com
  • Google Scholar
  • ORCId
  • Research Id
  • Publons

    • نشاطات التدريسي

    البحوث المنشورة

    المؤلفات

    المقررات المكلف بها

    المحاضرات

    مشاريع التخرج

    المقالات داخل المجلة

    المقررات المكلف بها

    المقررات المكلف بها

    المقررات المكلف بها - 1
    القسم المرحلة الفصل رمز المقرر الوحدات توصيف المقرر
    قسم تقنيات المختبرات الطبية المرحلة الثانية فصل اول 0 علم الاحياء الجزيئي/ عملي
    البحوث

    البحوث

    2023 ِAksaray university
    The JAK/STAT (Janus Kinase Transducers and Activators of Transcription) signaling pathway is involved in many cellular events such as cell growth, development, survival, tumorigenesis, and cell differentiation. But it is critical for immune cells and hematopoietic cells. Proper functioning of JAK/STAT pathway is necessary for the normal formation of blood cells. Mutations that may occur in this pathway may cause hematological cancers by disrupting JAK/STAT functionality. Leukemia is a type of hematological cancer of myeloid and lymphoid origin. JAK/STAT signaling pathway has become one of the appropriate targets in the treatment of leukemia, one of the hematological cancers. Therefore, in our study, the expression levels of JAK/STAT signaling pathway genes were investigated in bortezomib-treated HL-60 (acute myeloid leukemia) cell line to elucidate the role of JAK/STAT signaling pathway in hematological cancers. HL-60 leukemia cell line was propagated in cell culture. MTT analysis was performed to determine the IC50 value of bortezomib applied to the cell line. Then, cDNA synthesis was performed by RNA isolation. Expressions of JAK1, JAK2, JAK3, STAT1, STAT3, STAT5A and STAT5B genes in the JAK/STAT signaling pathway were analyzed using Real-Time qPCR. According to our findings, it was determined that JAK1, JAK2 and JAK3 gene expressions in the HL-60 cell line were statistically significantly decreased at all bortezomib doses. A significant decrease was observed in STAT1, STAT5A and STAT5B gene expressions at all doses. However, no decrease was observed in STAT3 gene expression at 20nM, while a lesser decrease was detected at other doses compared to STAT1 and STAT5(A,B) genes. In conclusion, bortezomib showed its anticancer effect on HL-60 leukemia cells by suppressing the JAK/STAT pathway. Thus, it may be possible to develop alternative treatment strategies for patients with acute myeloid leukemia by developing new inhibitory drugs specific to these suppressed JAK/STAT genes. Keywords: Acute .Myeloid Leukemia, HL-60 Cell Line, Bortezomib, JAK/STAT Signaling Pathway, Real-Time qPCR